NCT02363114 is a clinical trial in Stroke, sponsored by Dr. Richard H. Swartz.

Who is sponsoring NCT02363114?

NCT02363114 is sponsored by Dr. Richard H. Swartz.

What condition does NCT02363114 study?

NCT02363114 studies Stroke, Transient Ischemic Attack, Depression, Obstructive Sleep Apnea, Cognitive Impairment.

Is NCT02363114 still recruiting?

NCT02363114 is currently status unknown. Last updated 22 September 2021.

Last reviewed 2021-09-22 · How we verify

NCT02363114

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DOC Utility: Screening of Depression, Obstructive Sleep Apnea and Cognitive Impairment

Status unknown Last updated 22 September 2021

What this trial tests

trial in Stroke in 6,500 participants. Status unknown.

Timeline

1 April 2014

Primary endpoint
30 September 2017

1 December 2022

Quick facts

Lead sponsor	Dr. Richard H. Swartz
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	6,500
Start date	1 April 2014
Primary completion	30 September 2017
Estimated completion	1 December 2022
Sites	1 location across Canada

Conditions studied

Stroke — all drugs for Stroke →
Transient Ischemic Attack — all drugs for Transient Ischemic Attack →
Depression — all drugs for Depression →
Obstructive Sleep Apnea — all drugs for Obstructive Sleep Apnea →

Sponsor

Dr. Richard H. Swartz

Who can join

Eligibility, any sex, with Stroke or Transient Ischemic Attack. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to determine whether baseline DOC screening can add to clinical and demographic data to predict the occurrence of a composite negative outcome (any of: recurrent stroke, myocardial infarction, death, or admission to a long-term care (LTC) / complex continuing care (CCC) facility) within one year of screening, in stroke prevention clinic patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

DOC screen completion time reflects executive function, speed of processing and fluency in an observational cohort study
Southwell A, Sujanthan S, Armel T, Xing E, et al · · 2023 · DOI 10.1101/2023.02.15.23286004

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke · recruiting
NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
NCT07356011 — Exoskeleton for Balance · NA · recruiting
NCT07523503 — Unilateral Versus Bilateral Task-specific Training on Motor Impairment, Upper Extremity Function, and Hand Dexterity in · NA · recruiting
NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02363114 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dr. Richard H. Swartz
Last refreshed: 22 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02363114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing